ZA923310B - Pharmaceutical compositions comprising an anticytokine - Google Patents

Pharmaceutical compositions comprising an anticytokine

Info

Publication number
ZA923310B
ZA923310B ZA923310A ZA923310A ZA923310B ZA 923310 B ZA923310 B ZA 923310B ZA 923310 A ZA923310 A ZA 923310A ZA 923310 A ZA923310 A ZA 923310A ZA 923310 B ZA923310 B ZA 923310B
Authority
ZA
South Africa
Prior art keywords
anticytokine
pharmaceutical compositions
tbps
graft
versus
Prior art date
Application number
ZA923310A
Other languages
English (en)
Inventor
David Wallach
Wallach David
Dan Aderka
Aderka Dan
Hartmut Engelmann
Engelmann Hartmut
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA923310(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of ZA923310B publication Critical patent/ZA923310B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA923310A 1991-05-07 1992-05-07 Pharmaceutical compositions comprising an anticytokine ZA923310B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne

Publications (1)

Publication Number Publication Date
ZA923310B true ZA923310B (en) 1993-01-27

Family

ID=11062415

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923310A ZA923310B (en) 1991-05-07 1992-05-07 Pharmaceutical compositions comprising an anticytokine

Country Status (12)

Country Link
EP (2) EP0512528B1 (xx)
JP (1) JP3320774B2 (xx)
AT (2) ATE334695T1 (xx)
AU (1) AU1609492A (xx)
CA (1) CA2068027C (xx)
DE (2) DE69229975T2 (xx)
DK (2) DK0880970T3 (xx)
ES (2) ES2137935T3 (xx)
GR (1) GR3031805T3 (xx)
IL (1) IL98078A0 (xx)
PT (1) PT880970E (xx)
ZA (1) ZA923310B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
ATE196849T1 (de) * 1993-07-30 2000-10-15 Kennedy Inst Of Rheumatology Verfahren zur behandlung von multiplesklerose
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
ATE212231T1 (de) 1995-07-14 2002-02-15 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法
EP0942740B1 (en) 1996-12-06 2003-08-27 Amgen Inc., Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク. Opglへの抗体
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
PT1471974E (pt) 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG11201607881SA (en) 2014-03-31 2016-10-28 Kirin Amgen Inc Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
ATE119942T1 (de) * 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
ATE128184T1 (de) * 1989-12-13 1995-10-15 Yeda Res & Dev Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
RU2166955C2 (ru) * 1991-01-18 2001-05-20 Эмген Инк. Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0880970B1 (en) 2006-08-02
PT880970E (pt) 2006-12-29
JPH05170661A (ja) 1993-07-09
DE69233643D1 (de) 2006-09-14
DE69229975T2 (de) 2000-05-11
EP0512528A3 (en) 1993-07-21
ATE184488T1 (de) 1999-10-15
JP3320774B2 (ja) 2002-09-03
ATE334695T1 (de) 2006-08-15
DK0880970T3 (da) 2006-11-20
IL98078A0 (en) 1992-06-21
CA2068027C (en) 2003-09-23
GR3031805T3 (en) 2000-02-29
DK0512528T3 (da) 1999-12-20
ES2137935T3 (es) 2000-01-01
DE69233643T2 (de) 2007-07-26
EP0880970A1 (en) 1998-12-02
EP0512528A2 (en) 1992-11-11
AU1609492A (en) 1992-11-12
CA2068027A1 (en) 1992-11-08
EP0512528B1 (en) 1999-09-15
DE69229975D1 (de) 1999-10-21
ES2270479T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
ZA923310B (en) Pharmaceutical compositions comprising an anticytokine
EP0670730A4 (en) FUSION PROTEINS COMPRISING A TUMOR NECROSIS FACTOR RECEPTOR.
EP0168214A3 (en) Tumor necrosis factor, methods for its preparation, compositions containing it, dna encoding it and assay method using such dna
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
AU584608B2 (en) DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
IL128407A0 (en) A tumor necrosis factor related ligand
GR3000944T3 (en) Pharmaceutical composition containing thymus extract fractions
PL319040A1 (en) Modified proteins
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
AU1346488A (en) Arginine-depleted human tumor necrosis factor
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
AU7117687A (en) Combination therapy using interleukin-2 and tumor necrosis factor
EP0723016A3 (en) Leukocyte activation factor
ZA903843B (en) Tumor necrosis factor binding protein ii,its purification and antibodies thereto
ZA9010036B (en) Expression of the recombinant tumor necrosis factor binding protein i(tbp-i)
AU4194593A (en) Medicinal composition comprising TCF-II